(Q34707966)

4 August 2017

1 reference

title

From natural products to clinically useful antifungals (English)

1 reference

4 August 2017

1 reference

David Barrett

1

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

Biochimica et Biophysica Acta

4 August 2017

published in

1 reference

4 August 2017

volume

1587

1 reference

4 August 2017

issue

2-3

1 reference

4 August 2017

page(s)

224-233

1 reference

Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

Fungal infections in older adults

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

Lipid formulations of amphotericin B: recent progress and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

The future of antifungal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

Fungal cell wall inhibitors: emphasis on clinical aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

Chryscandin, a novel peptidyl nucleoside antibiotic. I. Taxonomy, fermentation, isolation and characterization.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

Chaetiacandin, a novel papulacandin. I. Fermentation, isolation and characterization

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

A novel antifungal antibiotic, FR-900848. I. Production, isolation, physico-chemical and biological properties

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

FR109615, a new antifungal antibiotic from Streptomyces setonii. Taxonomy, fermentation, isolation, physico-chemical properties and biological activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

Synthesis and structure determination of FR109615, a new antifungal antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

The fungal cell wall as a drug target

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

WF11899A, B and C, novel antifungal lipopeptides. I. Taxonomy, fermentation, isolation and physico-chemical properties.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

WF11899A, B and C, novel antifungal lipopeptides. II. Biological properties.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

FR901469, a novel antifungal antibiotic from an unidentified fungus No.11243. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological properties.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

FR901469, a novel antifungal antibiotic from an unidentified fungus No.11243. II. In vitro and in vivo activities

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

FR901469, a novel antifungal antibiotic from an unidentified fungus No. 11243. III. Structure determination

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

Synthesis and evaluation of LY121019, a member of a series of semisynthetic analogues of the antifungal lipopeptide echinocandin B

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

Synthesis and biological activity of novel macrocyclic antifungals: acylated conjugates of the ornithine moiety of the lipopeptidolactone FR901469.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

Novel amidine conjugates of the ornithine moiety of the macrocyclic antifungal lipopeptidolactone FR901469.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

Synthesis and biological activity of novel macrocyclic antifungals. modification of the tyrosine moiety of the lipopeptidolactone FR901469.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

Site-specific structural transformation of the novel antifungal cyclic depsipeptide FR901469: synthesis and biological activity of FR203903

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

Synthesis and antifungal activities of novel 1,3-beta-D-glucan synthase inhibitors. Part 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

Synthesis and antifungal activities of novel 1,3-beta-D-glucan synthase inhibitors. Part 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

Therapeutic effects of water-soluble echinocandin compounds on Pneumocystis pneumonia in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900085-6

7 January 2021

10.1016/S0925-4439(02)00085-6

Identifiers

DOI

1 reference

4 August 2017

1 reference